Genmab outlines royalty deal with Janssen
For the first time, Danish biotech company Genmab is getting specific about how big a share of sales from its blockbuster hopeful daratumumab it can expect to get from Big Pharma partner Janssen.
BY BENJAMIN WERNER CHRISTENSEN
Genmab has previously announced, rather vaguely, that it can receive double-digit royalties from its partner Janssen, should the two companies manage to launch multiple myeloma treatment daratumumab commercially, but the Danish biotech company is now getting more specific.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab has bagged USD 170 million in milestones
For abonnenter
Daratumumab up for accelerated assessment in EU
For abonnenter
New advance for Genmab's blockbuster in the making
For abonnenter
